Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics

Molecular Nutrition and Food Research

Volumn 52, Issue 7, 2008, Pages 772-779

  Gurley, Bill J ^a   Swain, Ashley ^b   Williams, D Keith ^b   Barone, Gary ^b   Battu, Sunil K ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Digoxin; Echinacea; Herb drug interactions; Pharmacokinetics; St. John's wort

Indexed keywords

CLARITHROMYCIN; DIGOXIN; FLAVONOID; GLYCOPROTEIN P; RIFAMPICIN;

ARTICLE; BLOOD; DIET SUPPLEMENTATION; ECHINACEA; GINKGO BILOBA; HERB DRUG INTERACTION; HYPERICUM; METABOLISM;

CLARITHROMYCIN; DIETARY SUPPLEMENTS; DIGOXIN; ECHINACEA; FLAVONOIDS; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HYPERICUM; P-GLYCOPROTEIN; RIFAMPIN;

EID: 53249094298     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700081     Document Type: Article

References (53)

1. Cupp, M. J., Herbal remedies: adverse effects and drug interactions, Am. Fam. Phys. 1999, 59, 1239-1244.
2. Ioannides, C., Pharmacokinetic interactions between herbal remedies and medicinal drugs, Xenobiotica 2002, 32, 451-478.
3. Zhou, S., Gao, Y., Jiang, W., Huang, M., et al., Interactions of herbs with cytochrome P450, Drug Metab. Rev. 2003, 35, 35-98.
4. Zhou, S., Lim, L. Y., Chowbay, B., Herbal modulation of P-glycoprotein, Drug Metab. Rev. 2004, 36, 57-104.
5. Mills, E., Wu, P., Johnston, B. C., Galliacano, K., Natural health product-drug interactions: a systematic review of clinical trials, Ther. Drug Monit. 2005, 27, 549-557.
6. Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., et al., Herb-drug interactions: a literature review. Drugs. 2005, 65, 1239-1282.
7. Johne, A., Roots, I., Clinical drug interactions with medicinal herbs, Evid. Based Integrative Med. 2005, 2, 207-228.
8. van den Bout-van den Beukel, C. J. P., Koopmans, P. P., van der Ven, A. J. A. M., DeSmet, P. A. G. M., et al., Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents, Drug Metab. Rev. 2006, 38, 477-514.
9. Ulbricht, C., Basch, E., Weissner, W., Hackman, D., An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration, Expert Opin. Drug Saf. 2006, 5, 719-728.
10. Lam, Y. W. F., Huang, S.-M., Hall, S. D. (Eds.), Herbal Supplements - Drug Interactions: Scientific and Regulatory Perspectives, Informa Healthcare, New York 2006.
11. Wold, R. S., Lopez, S. T., Yau, L., Butler, L. M., et al., Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications, J. Am. Diet. Assoc. 2005, 105, 54-63.
12. Shahrokh, L. E., Lukaszuk, J. M., Prawitz, A. D., Elderly herbal supplement users less satisfied with medical care than nonusers. J. Am. Diet. Assoc. 2005, 105, 1138-1140.
13. Gardiner, P., Graham, R. E., Legedza, A. T. R., Eisenberg, D. M., Phillips, R. S., Factors associated with dietary supplement use among prescription medication users, Arch. Intern. Med. 2006, 166, 1968-1974.
14. Venkataramanan, R., Komoroski, B., Strom, S., In vitro and in vivo assessment of herb drug interactions. Life Sci. 2006, 78, 2105-2115.
15. Gurley, B. J., Swain, A., Barone, G., Williams, D. K., et al., Effect of goldenseal (Hydrastis Canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans, Drug Metab. Dispos. 2007, 35, 240-245.
16. Gurley, B., Hubbard, M. A., Williams, D. K., Thaden, J., et al., Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, J. Clin Pharmacol. 2006, 46, 201-213.
17. Gurley, B. J., Barone, G. W., Williams, D. K., Carrier, J. C., et al., Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans, Drug Metab. Dispos. 2006, 34, 69-74.
18. Rengelshausen, J., Goggelmann, C., Burhenne, J., Riedel, K.-D., et al., Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. 2003, 56, 32-38.
19. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., et al., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J. Clin. Invest. 1999, 104, 147-153.
20. Lam, J. L., Shugarts, S. B., Okochi, H., Benet, L. Z., Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism, J. Pharmacol Exp. Ther. 2006, 319, 864-870.
21. Liu, F. F., Ang, C. Y. W., Heinze, T. M., Rankin, J. D., et al., Evaluation of major active components in St. John's wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation, J. Chromatogr. A 2000, 888, 85-92.
22. Molgaard, P., Johnsen, S., Christensen, P., Cornett, C., HPLC method validated for the simultaneous analysis of cichoric acid and alkamides in Echinacea purpurea planta and products. J. Agric. Food Chem. 2003, 51, 6922-6933.
23. nd edn., pp. 2645-2646.
24. nd edn.
25. Johne, A., Brockmöller, J., Bauer, S., Maurer, A. et al., Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum), Clin. Pharmacol. Ther. 1999, 66, 338-345.
26. Dürr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., et al., St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4, Clin. Pharmacol. Ther. 2000, 68, 598-604.
27. Mueller, S. C., Uehleke, B., Woehling, H., Petzsch, M., et al., Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clin. Pharmacol. Ther. 2004, 75, 546-557.
28. Wang, Z., Hamman, M. A., Huang, S.-M., Lesko, L. J., Hall, S. D., Effect of St. John's wort on the pharmacokinetics of fexofenadine, Clin. Pharmacol. Ther. 2002, 71, 414-420.
29. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., Kim, R. B., Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects, Clin. Pharmacol. Ther. 2003, 73, 41-50.
30. Xie, R., Tan, L. H., Polasek, E. C., Hong, C., et al., CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations, J. Clin. Pharmacol. 2005, 45, 352-356.
31. Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L., Abul-Ezz, S. R., Drug interaction between St. John's wort and cyclosporine, Ann. Pharmacother. 2000, 34, 1013-1016.
32. Bauer, S., Störmer, E., Johne, A., Krüger, H., et al., Alterations in cyclosporine A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br. J. Clin. Pharmacol. 2003, 55, 203-211.
33. Mai, I., Bauer, S., Perloff, E., Johne, A., et al., Hyperforin content determines the magnitude of the St. John's wort-cyclosporine drug interaction, Clin. Pharmacol. Ther. 2004, 76, 330-340.
34. Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., et al., St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Nalt. Acad. Sci. USA 2000, 97, 7500-7502.
35. Wentworth, J. M., Agostini, M., Love, J., Schwabe, J. W., Chatterjee, V. K. K., St. John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol. 2000, 166, R11-R16.
36. Arold, G., Donath, F., Maurer, A., Diefenbach, K., et al., No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract, Planta Med. 2005, 71, 331-337.
37. Geick, A., Eichelbaum, M., Burk, O., Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol Chem. 2001, 276, 14581-14587.
38. Schuetz, E. G., Schinkel, A. H., Relling, M. V., Schuetz, J. D., P-glycoprotein: a major determinant of rifampin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 1996, 93, 4001-4005.
39. Barnes, J., Anderson, L. A., Gibbons, S., Phillipson, J. D., Echinacea species [Echinacea angustifolia (DC) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench]: a reviewof their chemistry, pharmacology and clinical properties, J. Pharm. Pharmacol. 2005, 57, 929-954.
40. Budzinski, J. W., Foster, B. C., Vandenhoek, S., Arnason, J. T., An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial extracts and tinctures, Phytomedicine 2000, 7, 273-282.
41. Foster, B. C., Vandenhoek, S., Hana, J., Krantis, A., In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products, Phytomedicine 2003, 10, 334-342.
42. Strandell, J., Neil, A., Carlin, G., An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies, Phytomedicine 2004, 11, 98-104.
43. Matthias, A., Gillam, E. M. J., Penman, K. G., Matovic, N. J. et al., Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion, Chem. Biol. Interact. 2005, 155, 62-70.
44. Yale, S. H., Glurich, I., Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9, J. Altern. Complement. Med. 2005, 11, 433-439.
45. Hellum, B. H., Hu, Z., Nilsen, O. D., The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes, Basic Clin. Pharmacol. Toxicol. 2007, 100, 23-30.
46. Dietz, B., Heilmann, J., Bauer, R., Absorption of dodeca-2E,4E,8Z,10E/Z- tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture, Planta Med. 2001, 67, 863-864.
47. Matthias, A., Addison, R. S., Penman, K. G., Dickinson, R. G. et al., Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion, Life Sci. 2005, 77, 2018-2029.
48. Woelkart, K., Koidl, C., Grisold, A., Gangemi, J. D., Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans, J. Clin. Pharmacol. 2005, 45, 683-689.
49. Gorski, J. C., Huang, S.-M., Pinto, A., Hamman, M. A., et al., The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo, Clin. Pharmacol. Ther. 2004, 75, 89-100.
50. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto, Clin. Pharmacol. Ther., 2004, 76, 428-440.
51. Binns, S. E., Livesey, J. F., Arnason, J. T., Baum, B. R., Phytochemical variation in Echinacea from roots and flowerheads of wild and cultivated populations, J. Agric. Food Chem. 2002, 50, 3673-3687.
52. Gilroy, C. M., Steiner, J. F., Byers, T., Shapiro, H., Georgian, W., Echinacea and truth in labeling, Arch. Intern. Med. 2003, 163, 699-704.
53. Pellati, F., Benvenuti, S., Melegari, M., Lasseigne, T., Variability in the composition of anti-oxidant compounds in Echinacea species by HPLC. Phytochem. Anal. 2005, 16, 77-85.